Stock Events

Stock Events

XORTX THERAPEUTICS 

€2.02
36
-€0.48-19.2% Thursday 09:35

Statistics

Day High
2.04
Day Low
2.04
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

14MayExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.84
-0.54
-0.24
0.06
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2017
2018
2019
2020
2021
2022
0Revenue
-6.81MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ANU.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals is involved in developing treatments for cystic fibrosis and other diseases, potentially overlapping with XORTX's focus on kidney diseases and conditions that could have similar treatment approaches.
Aurinia Pharmaceuticals
AUPH
Mkt Cap2.08B
Aurinia Pharmaceuticals focuses on the development of therapies for autoimmune diseases, including lupus nephritis, which could compete with XORTX's kidney-focused therapies.
Akebia Therapeutics
AKBA
Mkt Cap369.67M
Akebia Therapeutics works on treatments for kidney disease and anemia, areas that overlap with XORTX's therapeutic focus, making them direct competitors.
Ardelyx
ARDX
Mkt Cap1.46B
Ardelyx focuses on kidney and cardiovascular diseases, offering treatments that could compete with XORTX's products for similar indications.
Trevena
TRVN
Mkt Cap9,501
Trevena develops therapies for central nervous system disorders but has potential overlap in treatment methodologies that could be applied to conditions XORTX targets.
Outlook Therapeutics
OTLK
Mkt Cap22.91M
Outlook Therapeutics is focused on ocular diseases but represents the broader competition in the biopharmaceutical sector, competing for investment and resources.

About

XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and acute kidney injury (AKI) associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. The company has a collaboration and license agreements with the Icahn School of Medicine to study the incidence of AKI and hyperuricemia in patients hospitalized with COVID-19; and with the University of Florida Research Foundation, Inc. XORTX Therapeutics Inc. is based in Alberta Beach, Canada.
Show more...
CEO
Employees
3
Country
DE
ISIN
CA98420Q4051
WKN
000A427MJ

Listings

F
DE
ANU.F
V
CA
XRTX.V
XNAS
US
XRTX
BOATS
BOATS
XRTX.BOATS

0 Comments

Share your thoughts

FAQ

What is XORTX THERAPEUTICS stock price today?▼
The current price of ANU.F is €2.02 EUR — it has decreased by -19.2% in the past 24 hours. Watch XORTX THERAPEUTICS stock price performance more closely on the chart.
What is XORTX THERAPEUTICS stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange XORTX THERAPEUTICS stocks are traded under the ticker ANU.F.
When is the next XORTX THERAPEUTICS earnings date?▼
XORTX THERAPEUTICS is going to release the next earnings report on May 14, 2026.
What were XORTX THERAPEUTICS earnings last quarter?▼
ANU.F earnings for the last quarter are -0.21 EUR per share, whereas the estimation was -0.71 EUR resulting in a +70.08% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is XORTX THERAPEUTICS revenue for the last year?▼
XORTX THERAPEUTICS revenue for the last year amounts to 0 EUR.
What is XORTX THERAPEUTICS net income for the last year?▼
ANU.F net income for the last year is -6.81M EUR.
How many employees does XORTX THERAPEUTICS have?▼
As of April 10, 2026, the company has 3 employees.
In which sector is XORTX THERAPEUTICS located?▼
XORTX THERAPEUTICS operates in the Health Care sector.
When did XORTX THERAPEUTICS complete a stock split?▼
XORTX THERAPEUTICS has not had any recent stock splits.